TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 0.700nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 1.60nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 1.60nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 1.83nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 1.90nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 2.10nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 2.5nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 2.60nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 2.80nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 2.80nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 3.20nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 3.28nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 3.30nMAssay Description:Compound binding to the ASK1 kinase active site was determined using the KINOMEscan Assay platform (DiscoverX, San Diego, Calif.). Briefly, ASK1-tagg...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 3.30nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 3.40nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 3.5nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 3.60nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 3.90nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 4nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 4.10nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 4.30nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 4.30nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 4.30nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 4.40nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 4.60nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 4.60nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 4.60nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 4.70nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 4.70nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 4.70nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 4.90nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 4.90nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 4.90nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 4.90nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 4.90nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 5nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 5.10nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 5.10nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 5.10nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 5.20nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 5.20nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 5.20nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 5.20nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 5.20nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 5.20nMAssay Description:Compound binding to the ASK1 kinase active site was determined using the KINOMEscan Assay platform (DiscoverX, San Diego, Calif.). Briefly, ASK1-tagg...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 5.30nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 5.30nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 5.40nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 5(Homo sapiens (Human))
Hepatikos Therapeutics
US Patent
Hepatikos Therapeutics
US Patent
Affinity DataIC50: 5.40nMAssay Description:Inhibition of ASK1 kinase activity was determined radiometrically using 33P substrate incorporation (Reaction Biology Corp., Malvern, Pa.). Briefly, ...More data for this Ligand-Target Pair